Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Ultragenyx Pharmaceutical Inc RARE

Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth... see more

Current News (NDAQ:RARE)

Ultragenyx to Participate in Investor Conferences in December

GlobeNewswire November 24, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 21, 2025

Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update

GlobeNewswire November 4, 2025

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

GlobeNewswire November 4, 2025

Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups

GlobeNewswire October 30, 2025

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

GlobeNewswire October 28, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 24, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 3, 2025

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

GlobeNewswire September 30, 2025
View More News ››

Opinion & Analysis (NDAQ:RARE)

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study

Streetwise Reports January 13, 2020
View More Opinion ››

Bullboard Posts (NDAQ:RARE)

Be the first to post on this bullboard.

Tidal Care Inc.

Tidal Care Inc.

Tidal Care aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the ...
View More »